Economic burden of long-term treatment of severe fecal incontinence.

Impacto económico del tratamiento a largo plazo de la incontinencia fecal grave.
Colostomy Colostomía Costes médicos Economic impact Fecal incontinence Impacto económico Incontinencia fecal Medical costs Neuroestimulación de raíces sacras Sacral nerve stimulation Symptomatic treatment Tratamiento sintomático

Journal

Cirugia espanola
ISSN: 2173-5077
Titre abrégé: Cir Esp (Engl Ed)
Pays: Spain
ID NLM: 101771152

Informations de publication

Date de publication:
15 May 2021
Historique:
received: 28 01 2021
revised: 14 04 2021
accepted: 14 04 2021
entrez: 19 5 2021
pubmed: 20 5 2021
medline: 20 5 2021
Statut: aheadofprint

Résumé

Find out the long-term economic cost associated with the treatment of severe fecal incontinence by SNS versus symptomatic conservative treatment and definitive colostomy. Detailed descriptive study of the costs of the healthcare process (interventions, consultations, devices, complementary tests, hospitalization, etc.) of 3 treatment alternatives for fecal incontinence using analytical accounting tools of the Health Service based on clinical activity data. The frequency of use of health resources or the quantity of products dispensed in pharmacies (medication, diapers, ostomy material, etc.) was estimated in each case. Costs derived from adverse situations were included. Patients with severe fecal incontinence, defined by a score greater than 9 on the Wexner severity scale, in whom first-line treatments had failed, were included. Data from a consecutive cohort of 93 patients who underwent an SNS between 2002 and 2016 were used; patients who underwent definitive colostomy (n=2); parastomal hernia (n=3), and colostomy stenosis (n=1). The mean cumulative cost in 10 years per patient in each alternative was: € 10,972.9 symptomatic treatment (62% diapers); € 17,351.57 SNS (95.83% interventions; 81.6% devices); € 25,858.54 definitive colostomy (70.4% ostomy material and accessories). Management of severe fecal incontinence implies a great burden in economic terms. The colostomy is the alternative that generates the most direct cost, followed by SNS and symptomatic treatment.

Identifiants

pubmed: 34006360
pii: S0009-739X(21)00156-1
doi: 10.1016/j.ciresp.2021.04.008
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Informations de copyright

Copyright © 2021 AEC. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Mario Javier de Miguel Valencia (MJ)

Servicio de Cirugía General, Hospital Reina Sofía, Tudela, Navarra, España. Electronic address: mariodemiguel85@gmail.com.

Alberto Margallo Lana (A)

Servicio de Control y Análisis del Coste, Departamento de Salud del Gobierno de Navarra, Pamplona, Navarra, España.

M Ángeles Pérez Sola (MÁ)

Servicio de Cirugía General, Hospital Reina Sofía, Tudela, Navarra, España.

Eduardo Sánchez Iriso (E)

Departamento de Economía, Área de Economía Aplicada, Universidad Pública de Navarra, Pamplona, Navarra, España.

Juan Manuel Cabasés Hita (JM)

Departamento de Economía, Área de Economía Aplicada, Universidad Pública de Navarra, Pamplona, Navarra, España.

Iñaki Alberdi Ibáñez (I)

Servicio de Cirugía General, Hospital Reina Sofía, Tudela, Navarra, España.

Miguel Ángel Ciga Lozano (MÁ)

Unidad de Cirugía Colorrectal, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.

Mario de Miguel Velasco (M)

Unidad de Cirugía Colorrectal, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.

Classifications MeSH